Forum for Science, Industry and Business
  • Sponsored by:
  • Siemens
  • Siemens
  • Siemens
Search our Site:

Topic (optional):

 

Home Reports Health and Medicine Content

Targeting Wolbachia, doxycycline reduces pathology of Lymphatic Filariasis

next article
19.09.2006

Lymphatic filariasis, a mosquito-borne tropical disease that afflicts 120 million people worldwide, can cause debilitating swelling of the legs and genital areas.

 

According to a new study published in the open access journal PLoS Pathogens, these pathologies can be treated with doxycycline, a tetracycline antibiotic. The treatment works by targeting Wolbachia bancrofti, a bacterial symbiote of the microscopic parasitical worms responsible for the disease.


Existing treatments for lymphatic filariasis kill the larvae of these worms, an effective measure against transmission, but offer only partial relief for people with adult worms in their blood. The studies suggest that doxycycline, which is already approved for human use, could provide an ameliorating treatment for persons suffering from the ailment, though mass treatment may still be a long way off.

Dr. Achim Hoerauf (University of Bonn, Germany) and colleagues used a double-blind trial in Ghana as the foundation of their report. In the course of the research, which was supported by grants from the European Commission and the VW-Foundation, 200 mg/day of doxycycline was administered to a sample group for a six week period. Follow ups at 4, 12, and 24 months showed a reduction in the pathology of the disease and an improvement in the condition of infected individuals.

Andrew Hyde | Source: alphagalileo
Further information: www.plos.org

next article

B2B Search

Product / Service
Company / Organisation

Latest News

Scientists find new insight into genome of neglected malaria parasite

10.10.2008 | Life Sciences

Hodgkin lymphoma -- new characteristics discovered

10.10.2008 | Life Sciences

Digital zebrafish embryo provides the first complete developmental blueprint of a vertebrate

10.10.2008 | Life Sciences